Welcome to our dedicated page for Forte Biosciences SEC filings (Ticker: FBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Forte Biosciences, Inc. filings document a clinical-stage biopharmaceutical issuer focused on FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related diseases. Its 8-K reports cover operating and financial results, Regulation FD clinical disclosures, material events, capital-structure matters and exhibits such as press releases and clinical presentations.
Proxy materials describe annual meeting matters, stockholder voting, board and compensation governance and equity incentive plan administration. The filing record also identifies Forte’s common stock, par value $0.001 per share, listed on Nasdaq under the symbol FBRX.
Forte Biosciences, Inc. filed a current report to note that it issued a press release with its financial results for the quarter ended September 30, 2025. The press release, dated November 14, 2025, is included as Exhibit 99.1 to the report.
Federated Hermes, Inc. and affiliated reporting persons disclosed beneficial ownership of 1,635,380 shares of Forte Biosciences, Inc. common stock, representing 13.15% of the class as of the event date. The filing lists Federated Hermes, Inc. (a Pennsylvania entity) and the Voting Shares Irrevocable Trust as holders with sole voting and dispositive power over the 1,635,380 shares, while three individuals — Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue — are reported with shared voting and dispositive power over the same aggregate amount.
The statement affirms the securities were acquired and are held in the ordinary course of business and were not acquired with the purpose of changing or influencing control of the issuer. The filing includes exhibits for classification of reporting persons, a joint filing agreement, and a power of attorney.
Riley Antony A reported disposition transactions in this Form 4 filing.
Forte Biosciences, Inc. chief financial officer Riley Antony A exercised 375 restricted stock units into an equal number of common shares on October 1, 2025. In connection with this vesting, 134 common shares were delivered at $14.52 per share to satisfy tax liability. Following these transactions, Antony directly holds 31,840 Forte Biosciences common shares and 1,875 RSUs remain outstanding under an award that vests one‑sixteenth on each quarterly vesting date, subject to continued service.
Paul A. Wagner, CEO, Secretary and Chair of Forte Biosciences, Inc. (FBRX), reported an award of 1,250 restricted stock units (RSUs) on 10/01/2025. Each RSU converts into one share of common stock at $0. The RSUs vest in 16 quarterly installments (one-sixteenth each) beginning on or immediately after February 1, 2023, subject to continued service under the 2021 Equity Incentive Plan. The report also shows a separate sale of 98 shares on 10/01/2025 at $14.52, leaving total beneficial ownership of 82,092 shares after the transactions.
Forte Biosciences filed a Form S-8 to register securities for an employee benefit plan and incorporates by reference prior S-8 registration statements and recent SEC reports, including its annual report for the fiscal year ended December 31, 2024 and quarterly reports for March 31, 2025 and June 30, 2025. The filing lists exhibits such as the specimen stock certificate, the 2020 Inducement Equity Incentive Plan and related award agreement forms, legal and audit consents, and a filing fee table.
Federated Hermes, Inc. and related parties reported ownership of 1,478,647 shares of Forte Biosciences, Inc. (common stock), representing 11.89% of the class. The Schedule 13G/A identifies Federated Hermes, Inc. (Pennsylvania) and the Voting Shares Irrevocable Trust as beneficial owners with sole voting and dispositive power over those shares. Individual reporting persons Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue are listed with shared voting and dispositive power over the same aggregate amount. The filing includes issuer address details and certifications that the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing control. Signatures on the filing are dated 09/05/2025 and the event date requiring the filing is noted as 08/31/2025.
Alger Associates, Inc. reports beneficial ownership of 1,618,649 shares of Forte Biosciences common stock, representing 13.3% of the class. Alger discloses sole voting power over 1,608,040 shares and sole dispositive power over 1,618,649 shares. The securities are held for one or more open-end investment companies or managed accounts advised by Fred Alger Management, LLC, a wholly owned subsidiary of Alger Group Holdings, LLC, which in turn is owned by Alger Associates, Inc. The filing indicates these holdings are held in the ordinary course of business and not for the purpose of changing or influencing control.
Forte Biosciences (FBRX) has a joint Schedule 13G/A showing Ikarian Capital, LLC and Neil Shahrestani report shared beneficial ownership of 617,667 shares of common stock, representing 4.99% of the company's outstanding stock. The reported holdings include 141,224 shares that may be acquired within 60 days upon exercise of warrants, although exercise is restricted to prevent exceeding the 4.99% threshold. The beneficial ownership is held through Ikarian Healthcare Master Fund and certain separately managed accounts, with Ikarian Capital acting as investment adviser and Mr. Shahrestani controlling Ikarian Capital. The filing states these securities are held in the ordinary course of business and not for the purpose of changing control.
Janus Henderson Group plc and an affiliated master fund report beneficial ownership of 657,509 shares of Forte Biosciences common stock, representing 9.9% of the class. The filing shows the reporting persons hold shared voting and shared dispositive power over these shares and report no sole voting or dispositive power. The statement certifies the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing also includes a power of attorney authorizing named compliance officers to execute related reporting documents.